Kirkland & Ellis takes lead role in $5 billion pharma deal

Kirkland & Ellis has scored a lead role in the $5 billion acquisition by Teva Pharmaceuticals of German generic drug manufacturer Ratiopharm. The Kirkland team will be led by partners David Fox and Volker Kullmann, and includes partners Björn Holland, Christian Zuleger, and Oded Schein. Teva usually turns to Willkie Farr & Gallagher for its US M&A work, and it has been suggested that Fox’s presence at Kirkland (Fox left Skadden for Kirkland 10 months ago) was the key reason that Kirkland was able to secure the lead role in the Teva-Ratiopharm deal. Freshfields Bruckhhaus Deringer advised Ratiopharm’s parent company on the deal, with a team led by partners Andreas Fabritius and Oliver von Rosenberg and including Christian Sistermann, Yorck Jetter, Marcel Kaufmann, Thomas Lübbig and Jochen Dieselhorst.

Kirkland & Ellis takes lead role in $5 billion pharma deal amlawdaily.typepad.com amlawdaily.typepad.com Fri, Mar 19, 2010

Related Lawfirms

Freshfields Bruckhaus Deringer LLP Kirkland & Ellis LLP Willkie Farr & Gallagher

Related Tags

Thomas Lübbig Skadden Oliver von Rosenberg Oded Schein Marcel Kaufmann Kirkland & Ellis Jochen Dieselhorst Germany Freshfields Bruckhhaus Deringer Deal David Fox Christian Zuleger Christian Sistermann Björn Holland Andreas Fabritius US Volker Kullmann Willkie Farr & Gallagher Yorck Jetter
Impressum (German) BigLaw on Facebook Follow us on Twitter Masters in Management (MiM) Programs Worldwide